A Randomized Non-Comparative Phase II Study of Nivolumab or Nivolumab/BMS-986205 alone or combined with Intravesical BCG in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

Brief description of study

If you have been diagnosed with BCG unresponsive, high-risk, non-muscle invasive bladder cancer, you may qualify for this study. The main purpose of the study is to assess the effectiveness (how well the drug works), safety, and tolerability of the investigational drugs called nivolumab or nivolumab with ID01 Inhibitor (BMS-986205) alone or combined with BCG (Bacille Calmette Guerin) in participants with BCG unresponsive, high-risk, non-muscle invasive bladder cancer.


Clinical Study Identifier: s18-00281
ClinicalTrials.gov Identifier: NCT03519256


If you are registered as a volunteer, please login to the dashboard to send referrals.